Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure - PubMed
5 hours ago
- #drug survival
- #psoriasis
- #biologics
- The study examines drug survival rates for bimekizumab, guselkumab, and risankizumab in psoriasis patients after failure of a secondary IL-17 inhibitor.
- Research compares interclass switching (to IL-23 inhibitors) versus intraclass switching (to another IL-17 inhibitor) for optimal sequential therapy after IL-17 inhibitor failure.
- Evidence suggests interclass switching to IL-23 inhibitors may outperform intraclass switching to another IL-17 inhibitor in terms of efficacy.
- Systematic reviews and meta-analyses support the evaluation of switching biologic agents in psoriasis treatment strategies.
- Single-center experiences with bimekizumab show its use in patients previously exposed to interleukin-17 inhibitors.